⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 30, 2019Interní medicína pro praxiOpen Access

Dangerous multiresistant bacteria "superbugs" in contemporary medicine

View Full Paper

Ask AI

Bookmark

Share

Abstract

NebezpečNé multirezisteNtNí bakterie "superbugs" v současNé medicíNě Nebezpečné multirezistentní bakterie "superbugs" v současné medicíně prof.MUDr.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Milan Kolář (2019) studied this question.

synapsesocial.com/papers/6aa9edcf71e43eb1ac557d54 https://doi.org/10.36290/int.2019.021

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing <i>Enterobacteriaceae</i> : Importance of Inadequate Initial Antimicrobial TreatmentCohort Study · 2007 · 461 citations
2Epidemiology of hospital-acquired pneumonia: Results of a Central European multicenter, prospective, observational study compared with data from the European regionCohort Study · 2016 · 63 citations
3Utilization of fluoroquinolones andEscherichia coli resistance in urinary tract infection: inpatients and outpatientsRetrospective Study · 2005 · 29 citations
4The structure of β-lactamasesOriginal Research · 1980 · 1,837 citations
5Updated Functional Classification of β-LactamasesOriginal Research · 2009 · 2,357 citations

More related papers

Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies2012
Incidence of fecal Enterobacteriaceae producing broad-spectrum beta-lactamases in patients with hematological malignancies2014
Molecular mechanisms of polymyxin resistance and detection of mcr genes2018

More from Interní medicína pro praxi

Central‑acting and alpha-1 adrenoreceptor blocking antihypertensives (fifth‑line antihypertensive agents)Sun,
Dual inhibition of at1 receptor for angiotensin ii and neprilysin or sacibtril‑valsartanFri,